DryShips Inc. (NASDAQ:DRYS) stock is sinking by 16% in Tuesday’s trading session, after the controversial shipping company reported a serious loss in its fourth quarter results of $84.6 million (which translates into a loss of $54.16 per share). The market is also very concerned that while DRYS does have cash to hand ($243 million) this money has already been earmarked for new vessel acquisitions. This is a problem because the company announced very poor operating cash flow with adjusted EBITDA at negative $13.9 million. If the money continues to spill from DRYS before its new vessels arrive (the first vessel is scheduled for June) then serious financial trouble lies ahead. If you want to learn more about DRYS check out this article on why investors are angry at DRYS CEO George Economou.
Gilead Sciences, Inc. (NASDAQ:GILD) are trading down by 9% after the healthcare giant announced guidance for the year far below Wall Street’s previous expectations. Specifically, full year net product sales are now forecast at $22.5 billion and $24.5 billion- versus the market expectation of $26.3 billion, due to weak predicted sales of just $7.5 billion to $9 billion for the pharma’s primary range of Hep-C drugs Sovaldi, Harvoni, and Epclusa. Gilead also released disappointing Q4 results with revenue for the quarter down to $7.3 billion- a drop of 15% while R&D was up a significant 60%. EPS was down by 19%. The drop in share price is estimated to have wiped approximately $9 billion from GILD’s market cap in a single day.
Out of the 13 analysts who published recommendations on Gild in the last three months, 9 rate the stock a buy and 4 rate the stock a hold. There are no sell recommendations. The average analyst price target of $85.20 is now a 29.68 % upside from the current share price of $65.93.
Galena Biopharma Inc (NASDAQ:GALE) shares tanked by 40% after the company announced a stock offering which priced the shares at a discount to their market value. Galena plans to raise $17 million from the public offering of common stock and stock warrants. The offering saw the shares priced at just $1 versus the closing price of the stock on Feb 7 of $1.40. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets including GALE-401 as well as cancer immunotherapy programs. Galena did not state its plans for the sale proceeds.